PD-L1 Antibody Selection by Tumor Mutation Load in Bladder Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for metastatic urothelial bladder cancer are limited, and there is a need for improved diagnostic methods and treatments, particularly for patients with high mutation loads in specific genes, as identified by somatic mutations.
Innovation Solution
The use of a PD-L1 binding antagonist antibody, specifically designed with defined heavy and light chain variable regions, for treating urothelial bladder cancer in patients with elevated mutation loads in certain genes, and methods for predicting treatment responsiveness based on mutation load analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PD-L1 axis binding antagonist is administered to all bladder cancer patients, then immune response suppression is addressed, but treatment efficacy is reduced due to patient heterogeneity in somatic mutation levels
Solution Approach 1:
The patent applies preliminary action by determining somatic mutation levels in tumor samples before administering PD-L1 axis binding antagonists. This pre-treatment genetic characterization allows clinicians to identify patients with elevated somatic mutations who are most likely to respond to immunotherapy, ensuring the treatment is given in advance to the right patient population before treatment heterogeneity reduces efficacy
Solution Approach 2:
The patent applies local quality by tailoring the treatment approach to specific patient subgroups based on their tumor's somatic mutation profile. Rather than uniform treatment, patients are stratified into those with elevated somatic mutations (who benefit from PD-L1 antagonists) and those without (who may require alternative therapies), making the treatment quality adapted to each patient's specific biological characteristics
2Measurement precision
If comprehensive genetic testing is performed on all tumor samples, then patient selection accuracy is improved, but diagnostic complexity and cost increase
Solution Approach 1:
The patent applies taking out by extracting and focusing analysis on specific genes known to be associated with elevated somatic mutations and response to PD-L1 axis binding antagonists. Rather than analyzing the entire genome, the method identifies and tests for mutations in particular candidate genes, simplifying the diagnostic process while maintaining patient selection accuracy
Solution Approach 2:
The patent applies parameter changes by establishing specific thresholds for somatic mutation levels that define responsive versus non-responsive patient populations. By setting quantitative criteria (elevated versus reference levels) for treatment selection, the method transforms complex genetic data into clear, actionable binary decisions that simplify clinical implementation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances therapeutic efficacy by targeting PD-L1 to restore T-cell function in patients with high mutation loads, potentially extending survival and improving treatment outcomes for metastatic and locally advanced urothelial bladder cancer.
Implementation Method 1
PD-L1 regulates the immune response by binding to an inhibitory receptor, known as programmed death 1 (PD-1), which is expressed on the surface of T-cells, B-cells, and monocytes. PD-L1 negatively regulates T-cell function also through interaction with another receptor, B7-1. Formation of the PD-L1/PD-1 and PD-L1/B7-1 complexes negatively regulates T-cell receptor signaling, resulting in the subsequent downregulation of T-cell activation and suppression of anti-tumor immune activity.
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient.